Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a co-packaged therapeutic kit containing a combination of proton pump inhibitor (Esomeprazole), antibiotic (Amoxicillin), and nitroimidazole (Clarithromycin). It is specifically engineered to target *Helicobacter pylori* infection in the gastric mucosa.
## Primary Indications
Treatment of *Helicobacter pylori* infection to reduce the risk of duodenal ulcer recurrence.
## Adult Dosing
* **Regimen:** Administered as a triple therapy kit twice daily (morning and evening).
* **Each dose typically includes:**
* Esomeprazole: 40 mg
* Amoxicillin: 1000 mg
* Clarithromycin: 500 mg
* **Duration:** 7 to 14 days, depending on local resistance patterns and regional treatment guidelines.
## Pediatric Dosing
Not recommended for pediatric use. Efficacy and safety have not been established in children.
## Dose Adjustments
* **Renal Impairment:** Dose adjustments for Amoxicillin and Clarithromycin are required in severe renal impairment (CrCl < 30 mL/min).
* **Hepatic Impairment:** Use caution with Clarithromycin in patients with hepatic impairment; dose reduction or avoidance may be necessary.
* **Geriatric:** No specific adjustment required based on age alone, but monitor renal/hepatic function.
## Contraindications
* Known hypersensitivity to Esomeprazole, substituted benzimidazoles, Amoxicillin (penicillins), or Clarithromycin (macrolides).
* Concomitant use of pimozide, cisapride, ergotamine, or dihydroergotamine due to risk of cardiac arrhythmias.
* History of cholestatic jaundice or hepatic dysfunction associated with macrolide use.
## Adverse Effects
* **Common:** Diarrhea, dysgeusia (metallic taste), nausea, abdominal pain, and headache.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe cutaneous adverse reactions (SCARs/Stevens-Johnson syndrome), QT prolongation (Clarithromycin), and anaphylaxis.
## Key Drug Interactions
* **CYP3A4 substrates:** Clarithromycin is a potent inhibitor; may elevate levels of warfarin, statins (e.g., simvastatin, atorvastatin), and colchicine.
* **pH-dependent drugs:** Esomeprazole reduces absorption of drugs requiring acidic gastric pH (e.g., atazanavir, ketoconazole).
* **Methotrexate:** PPIs may increase methotrexate levels, especially in high-dose therapy.
## Monitoring
* Monitor for signs of *C. difficile* infection (persistent diarrhea).
* Assess for hypersensitivity reactions (rash, angioedema).
* Monitor periodic renal/hepatic labs in patients on long-term or repeated courses.
* Monitor INR if patient is on warfarin.
## Clinical Pearls
* **Adherence:** High pill burden requires patient counseling to ensure complete course completion to prevent antibiotic resistance.
* **Administration:** Esomeprazole should be taken at least 60 minutes before a meal for optimal acid control.
* **Bismuth usage:** In regions with high clarithromycin resistance (>15%), bismuth-based quadruple therapy is often preferred over this triple therapy. Verify local antibiogram data.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by region and institution. Always verify dosages, contraindications, and drug interactions against current local prescribing information, institutional protocols, and official product monographs before prescribing or dispensing.
